Target type: biologicalprocess
The process in which the anatomical structures of skeletal joints are generated and organized during the embryonic phase. A skeletal joint is the connecting structure between the bones of the skeleton. [GOC:bf, GOC:BHF, GOC:dph, UBERON:0000982]
Embryonic skeletal joint morphogenesis is a complex and tightly regulated process that involves the coordinated interaction of multiple cell types, signaling pathways, and extracellular matrix components. It begins with the condensation of mesenchymal cells into cartilaginous models of future bones. At the sites where joints will form, a specialized region known as the interzone develops. This interzone is characterized by a lack of chondrogenesis and the presence of specific signaling molecules, such as Wnt, Shh, and BMP. These signals promote the differentiation of mesenchymal cells into chondrocytes, which then form the articular cartilage that will cover the ends of the bones. In addition, they induce the formation of the joint capsule, which surrounds and stabilizes the joint. The formation of the joint cavity is another crucial step in joint morphogenesis. This cavity is formed by the breakdown of the interzone, which is mediated by a specialized population of cells called chondroclasts. The chondroclasts degrade the cartilage matrix in the interzone, creating a space between the developing bones. This process is also regulated by signaling molecules, such as TGF-beta and MMPs. Finally, the formation of ligaments and tendons is necessary for proper joint function. These structures are formed by the differentiation of mesenchymal cells into fibroblasts, which then produce the collagen fibers that make up the ligaments and tendons. The formation of ligaments and tendons is also regulated by signaling molecules, such as Wnt and BMP. In summary, embryonic skeletal joint morphogenesis is a complex process involving a multitude of molecular and cellular events. The coordinated regulation of these events ensures the formation of functional joints that enable movement and support.'
"
Protein | Definition | Taxonomy |
---|---|---|
Protein odd-skipped-related 1 | A protein odd-skipped-related 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8TAX0] | Homo sapiens (human) |
Hyaluronidase-1 | A hyaluronidase-1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q12794] | Homo sapiens (human) |
Bone morphogenetic protein 4 | A bone morphogenetic protein 4 that is encoded in the genome of human. [PRO:CNA, UniProtKB:P12644] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
staurosporine | indolocarbazole alkaloid; organic heterooctacyclic compound | apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector | |
ferulic acid | ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid. | ferulic acids | anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; MALDI matrix material; plant metabolite |
caffeic acid | trans-caffeic acid : The trans-isomer of caffeic acid. | caffeic acid | geroprotector; mouse metabolite |
isoferulic acid | isoferulic acid : A ferulic acid consisting of trans-cinnamic acid bearing methoxy and hydroxy substituents at positions 4 and 3 respectively on the phenyl ring. isoferulic acid: isomer of ferulic acid; structure | ferulic acids | antioxidant; biomarker; metabolite |
rosmarinic acid | (R)-rosmarinic acid : A stereoisomer of rosmarinic acid having (R)-configuration. rosmarinic acid : The 1-carboxy-2-(2,4-dihydroxyphenyl)ethyl ester of trans-caffeic acid. rosmarinic acid: RN given refers to parent cpd; promote OT project | rosmarinic acid | geroprotector; plant metabolite |
dorsomorphin | dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling. dorsomorphin: an AMPK inhibitor | aromatic ether; piperidines; pyrazolopyrimidine; pyridines | bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor |
ldn 193189 | LDN 193189: inhibits bone morphogenetic protein signaling | pyrimidines | |
ml347 | ML347: an ALK2 inhibitor; structure in first source |